급성 편두통에 대한 피하용 Sumatriptan의 효과

Abstract

Migraine headache is thought to be associated with a dilatation of cranial blood vessels and an accompanying localized sterile inflammatory response. Sumatriptan, a selective agonist of 5-hydroxytryptamine receptors, blocks these phenomena. The efficacy and safety of sumatriptan in migraine were evaluated in this study. Twenty-six patients with 1 to 2 degree acute migraine were treated with a self-injection of 6mg Sumatriptan at home The outcome measures were the relief of headache and side effects within 2 hours of injection. Eighteen patients had migraine without aura, and the other eight had migraine with aura. Migraine attacks were improved in 75.6% (34 of 45 attacks) within 2 hours after sumatriptan injection. The rate of improvement was 80.8% (21 of 26 attacks) in first attacks and 68.4% (13 of 19 attacks) in second attacks. The efficacy of sumatriptan had no differences between migraine without aura and with aura. Adverse events were experienced by 34.6% of the patients. Most of them were minor and transient. Therefore subcutaneous sumatriptan self-injection is an effective treatment in migraine attacks. The side effects are minor and transient.